Demographic Characteristics And Peripheral Blood Clinical Laboratory Variables Predict Irae Occurrence In Patients With Advanced Melanoma Receiving Anti-Pd-1 Monotherapy.

Background: Although immune-related adverse effects (irAEs) are commonly seen in anti-PD-1 monotherapy-treated patients, their predictive biomarkers are still lacking. Methods: In this retrospective analysis, clinical data were collected from 141 advanced melanoma patients treated with anti-PD-1 monotherapy at Massachusetts General Hospital from Sept. 2009 to Dec. 2017. Demographic characteristics, baseline, and early-on-treatment (median 3 weeks after anti-PD-1 monotherapy initiation) routine laboratory variables were collected and correlated with occurrence of irAEs in both univariate and multivariate analyses. Results: 80/141 (56.7%) patients developed irAEs after anti-PD-1 monotherapy initiation. Significant independent predictive variables (P Conclusions: Scoring system based on simple, easily accessible, and routinely tested biomarkers could be used to help predict the risk of irAEs occurrence in anti-PD-1 monotherapy-treated advanced melanoma patients. Citation Format: Xue Bai, Michelle S. Kim, Gyulnara Kasumova, Justine Cohen, Donald Lawrence, Christine Freedman, Riley Fadden, Krista Rubin, Tatyana Sharova, Keith Flaherty, Ryan Sullivan, Genevieve Boland. Demographic characteristics and peripheral blood clinical laboratory variables predict irAE occurrence in patients with advanced melanoma receiving anti-PD-1 monotherapy [abstract]. In: Proceedings of the AACR Special Conference on Melanoma: From Biology to Target; 2019 Jan 15-18; Houston, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(19 Suppl):Abstract nr B25.